Navigation Links
Telik Announces Patents on Compounds Related to TELINTRA
Date:6/10/2008

PALO ALTO, Calif., June 10 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK), announced today that the European Patent Office has issued notices of allowance for two applications covering new compounds related to one of Telik's lead clinical candidates, TELINTRA(R). Corresponding applications have already issued as patents in the United States; and other applications are pending in major countries worldwide.

TELINTRA is currently in Phase 2 clinical trials for the treatment of Myelodysplastic Syndrome, a form of pre-leukemia, and for Chemotherapy Induced Neutropenia, a common side effect of chemotherapy. Telik expects these applications and patents to provide broad intellectual property protection to compounds related to TELINTRA, according to Derek Freyberg, Ph.D., Telik's VP, Intellectual Property. The patents will help to broaden and strengthen Telik's intellectual property estate and may support additional clinical development candidates.

About Telik

Telik, Inc. of Palo Alto, California, is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA, a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP(R), which enables the rapid and efficient discovery of small molecule drug candidates.

This press release contains "forward-looking" statements, including statements regarding the impact and coverage of patents on Telik's intellectual property. These forward-looking statements are based upon Telik's current expectations. There are important factors that could cause Telik's results to differ materially from those indicated by these forward-looking statements, including, among others, if clinical trials of TELINTRA are delayed or unsuccessful, Telik's business would suffer, if Telik's competitors develop and market products that are more effective than its product candidates, or obtain marketing approval before Telik does, Telik's commercial opportunity will be reduced or eliminated, and if Telik does not obtain regulatory approval to market products in the U.S. and foreign countries, Telik will not be permitted to commercialize these product candidates. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Telik's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its quarterly report on Form 10-Q for the quarter ended March 31, 2008. Telik does not undertake any obligation to update forward-looking statements contained in this press release.

TELIK, the Telik logo, TELINTRA, TELCYTA, and TRAP are trademarks or registered trademarks of Telik, Inc.


'/>"/>
SOURCE Telik, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Telik Announces Preclinical Presentations at AACR Annual Meeting
2. Telik Reports Positive Results From Phase 1 Dose-Escalation Study of TELINTRA Tablets in Myelodysplastic Syndrome
3. Selective Insurance Group Announces Officer Appointments
4. Nonin(R) Medical Announces Strategic Relationship With Microsoft and its Microsoft HealthVault Platform
5. Shared Health(R) Announces New Data Exchange Platform
6. China Sky One Medical, Inc. Announces Guidance for Second Quarter and Full Year 2008
7. Insulet Corporation Announces Private Offering of $65 Million of Convertible Senior Notes
8. NBTY Announces Agreement to Purchase Leiner Health Products
9. CorVel Announces Record Earnings
10. SUA Insurance Company Announces Partnership With American Safety Indemnity Company
11. WellPoint Announces Appearance at Upcoming Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... Cirracore Enterprise ... enterprises move workloads to the cloud. Cirracore provides a secure VMware® vCloud ... traversing the Internet. Transformation Solutions (TSL Partners) provides a full range of ...
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... ... specialty pharmacies, announces today the continuation of the ‘Pay It Forward’ program into ... prescription referral received at our specialty pharmacy. , “Since our Pay It ...
(Date:2/9/2016)... ... February 09, 2016 , ... On January 12, 2016 Paul ... appointment after they noticed their furnace not producing any heat. Shortly after entering the ... cracked heat exchanger was leaking dangerous levels of carbon monoxide into the home, at ...
(Date:2/9/2016)... ... February 09, 2016 , ... The ... Herberger’s and Younkers department stores, announced it has raised $176,000 to benefit the ... Holden Comprehensive Cancer Center at the University of Iowa, The Lynn Sage Cancer ...
(Date:2/9/2016)... ... 09, 2016 , ... ZipHearing.com is proud to ... hearing aids , increase industry transparency, and promote awareness of hearing solutions ... “For the average consumer, the hearing aid industry is esoteric and difficult to ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... N.J. , Feb. 9, 2016  Bluestar Silicones ... (LSR) product line for long-term implant applications and ... Medical Design & Manufacturing (MD&M) West Conference (Booth ... --> --> ... Silbione® Biomedical LSRs offer outstanding physical properties enabling ...
(Date:2/8/2016)... Respiratory Devices - Medical Devices Pipeline ... sector report, " Respiratory Devices - Medical Devices ... Respiratory Devices currently in pipeline stage. The ... with comparative analysis of the products at various ... involved in the pipeline product development. It also ...
(Date:2/8/2016)... 8, 2016 CBG Technologies, a U.S. ... Solvent Recycling Systems, specifically designed for precision parts ... new and existing vapor degreasers, parts washers and ... through continuous recycling and recovers 100% of the ... --> Precision parts manufacturers benefit from ...
Breaking Medicine Technology: